The White House
Pamela Melroy – Deputy Administrator, National Aeronautics and Space Administration
Sarah Bianchi – Deputy United States Trade Representative
Jayme White – Deputy United States Trade Representative
Robin Ashton – Inspector General, Central Intelligence Agency
Robert Bonnie – Under Secretary for Farm Production and Conservation, Department of Agriculture
Gwen Graham – Assistant Secretary for Legislation and Congressional Affairs, Department of Education
Mara Karlin – Assistant Secretary for Strategy, Plans, and Capabilities, Department of Defense
Taryn Williams – Assistant Secretary of Disability and Employment Policy, Department of Labor
Pamela Melroy, Nominee for Deputy Administrator, National Aeronautics and Space Administration
Pam Melroy (Colonel, USAF, ret) is an aerospace executive with government and industry experience across civil, commercial, and national security space. She is a retired U.S. Air Force test pilot and former NASA ast
This Week:
President Biden announced the U.S. will withdraw all of its troops from Afghanistan by September 11
th 2021, saying it’s time to end America’s longest war. The deadline, pushed back from the Trump administration’s original May withdrawal, will now fall on the 20-year anniversary of the September 11
th attacks. Jared and FOX News Sunday Anchor Chris Wallace discuss the President’s decision and the risk involved.
This week, the FDA and CDC recommended a pause in the distribution of the Johnson & Johnson COVID-19 vaccine. This comes after reports of rare blood clot side effects in six U.S. women who received the shot, resulting in one death. FOX News Washington Correspondent Rachel Sutherland speaks with Professor of Surgery and Health Policy at the Johns Hopkins University School of Medicine and FOX News Medical Contributor Dr. Marty Makary on the decision to pause the vaccine and what the process entails when a medicine is paused.
WASHINGTON – Today, President Joe Biden announced his intent to nominate eight leaders to key Administration posts:
Pamela Melroy – Deputy Administrator, National Aeronautics and Space Administration
Sarah Bianchi – Deputy United States Trade Representative
Jayme White – Deputy United States Trade Representative
Robin Ashton – Inspector General, Central Intelligence Agency
Robert Bonnie – Under Secretary for Farm Production and Conservation, Department of Agriculture
Gwen Graham – Assistant Secretary for Legislation and Congressional Affairs, Department of Education
Mara Karlin – Assistant Secretary for Strategy, Plans, and Capabilities, Department of Defense
Taryn Williams – Assistant Secretary of Disability and Employment Policy, Department of Labor
Pamela Melroy, Nominee for Deputy Administrator, National Aeronautics and Space Administration
MindMaze Defines the Future of Brain Health with Digital Neurotherapeutics Portfolio
Provides an Update on the Product Portfolio and Clinical Pipeline
News provided by
Share this article
LAUSANNE, Switzerland, April 15, 2021 /PRNewswire/
MindMaze Healthcare (MMHC), a global pioneer in the multibillion-dollar digital neurotherapeutics market, today shared its roadmap for its commercial product portfolio and clinical pipeline.
MindMaze Healthcare is at the forefront of advancing innovative digital neurotherapeutics (DTx) solutions through a platform approach that combines highly engaging serious game-based software supported by tailored smart peripherals that target two distinct areas: neurorehabilitation (Rehab DTx) and neuro-restoration (Neuro DTx).
MindMaze s serious digital therapeutics (DTx), a combination of neuroscience and AI-powered, immersive game-based activities are enhancing clinical outcomes for patients with neurological conditions including stroke, TBI
Why the AstraZeneca vaccine was plagued with errors
In the span of a year, AstraZeneca has gone from favoured child to problem child after a series of unforced errors by the British pharma company turned hope into hesitancy.
AstraZeneca, we have a problem..
Illustration: David Rowe
Apr 16, 2021 – 12.00am
Share
Mene Pangalos, head of biopharmaceuticals research for AstraZeneca, went to bed on Monday, March 22, feeling good for the first time in a while. After working around the clock through the weekend, he’d just announced better-than-expected interim results from the company’s large US vaccine trial: The shot was safe and 79 per cent effective at preventing cases of symptomatic COVID-19. Positive news, at last, after months of questions about everything including safety and supply shortfalls.